Dr. Reddy's Laboratories (500124) Resumen de Acciones
Dr. Reddy's Laboratories Limited, junto con sus filiales, opera como empresa farmacéutica integrada en todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 5/6 |
| Dividendos | 5/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en 500124 a partir de nuestros controles de riesgos.
500124 Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Dr. Reddy's Laboratories Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | ₹1,356.85 |
| Máximo en las últimas 52 semanas | ₹1,414.40 |
| Mínimo de 52 semanas | ₹1,149.00 |
| Beta | 0.26 |
| Cambio en 1 mes | 4.14% |
| Variación en 3 meses | 12.21% |
| Cambio de 1 año | 6.26% |
| Variación en 3 años | 30.73% |
| Variación en 5 años | 22.49% |
| Variación desde la OPV | 39,760.40% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 25
500124: Lower Profitability Expectations Will Restrain Future Share Price Upside
Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.
Actualización de narrativa • Jun 05
500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes
Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.
Actualización de narrativa • May 22
500124: Fair Outlook Will Balance Injectable Diabetes Launches And Compliance Developments
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories up from ₹1,314 to about ₹1,332. This change reflects updated assumptions around revenue growth, profit margins and future P/E expectations.Recent updates
Actualización de narrativa • Jun 25
500124: Lower Profitability Expectations Will Restrain Future Share Price Upside
Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.Actualización de narrativa • Jun 05
500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes
Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.Actualización de narrativa • May 22
500124: Fair Outlook Will Balance Injectable Diabetes Launches And Compliance Developments
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories up from ₹1,314 to about ₹1,332. This change reflects updated assumptions around revenue growth, profit margins and future P/E expectations.Actualización de narrativa • May 03
500124: Future Tax Compliance And Regulatory Setbacks Will Curb Share Price Upside
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,024, explaining that small adjustments to revenue growth, profit margin and future P/E assumptions did not materially change their overall price target view. What's in the News Health Canada granted Dr. Reddy's a Notice of Compliance for its generic Semaglutide Injection, allowing commercialization and sale in Canada.Actualización de narrativa • Apr 19
500124: Future Tax And Regulatory Compliance Issues Will Limit Upside Potential
Analysts have revised their price target for Dr. Reddy's Laboratories to ₹1,024, reflecting updated assumptions of higher revenue growth of 5.96%, a profit margin of 16.95% and a lower future P/E of 17.43x. What's in the News Launch of Obeda, an injectable semaglutide for type 2 diabetes in India, following Drugs Controller General of India approval for generic semaglutide.Actualización de narrativa • Apr 05
500124: Fair Outlook Will Balance Biosimilar Opportunity And Compliance Developments
Analysts have increased their price target on Dr. Reddy's Laboratories by about ₹13 to ₹1,314, citing updated assumptions that include a different discount rate, revised revenue growth and profit margin estimates, and an adjusted future P/E multiple. What's in the News Board meeting scheduled for March 24, 2026, to amend the Code of Practices and Procedures for Fair Disclosures of Un published Price Sensitive Information, signaling a focus on disclosure norms and compliance (company filing).Actualización de narrativa • Mar 21
500124: Biosimilar Pipeline Progress Will Drive Future Upside Despite GST Disputes
Analysts have maintained their price target for Dr. Reddy's Laboratories at ₹1,615. This reflects only minor adjustments to revenue growth, profit margin and forward P/E assumptions, rather than a change in the overall valuation view.Actualización de narrativa • Mar 07
500124: Biosimilar Approvals Will Drive Future Upside Despite Regulatory And Tax Overhang
Analysts have kept their price target for Dr. Reddy's Laboratories unchanged at ₹1,615, citing only marginal tweaks to revenue growth, profit margin and forward P/E assumptions that do not materially alter their valuation view. What's in the News The USFDA has accepted review of Dr. Reddy's 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to ORENCIA (abatacept) for multiple autoimmune indications, supported by analytical, PK and clinical data, including an ongoing Phase 3 trial (company announcement).Actualización de narrativa • Feb 21
500124: Biosimilar Pipeline And New Launches Will Drive Future Upside
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories slightly higher from about ₹1,611 to roughly ₹1,615 per share, reflecting updated assumptions on revenue growth, profit margins, and the future P/E multiple in their models. What's in the News US FDA accepted review of a 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to Orencia (abatacept), for multiple rheumatoid and arthritis indications in adults and children, backed by analytical, PK, and clinical data including Phase 1 PK similarity and an ongoing Phase 3 trial (company announcement).Actualización de narrativa • Feb 07
500124: Future Regulatory And Tax Compliance Risks Will Limit Upside Potential
Analysts have raised their fair value estimate for Dr. Reddy's Laboratories from ₹990 to ₹1,024, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E as key drivers of this change. What's in the News Launched OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent to Extra Strength Pataday Once Daily Relief, for temporary relief of itchy eyes caused by allergens.Actualización de narrativa • Jan 23
500124: Biosimilar Approvals And New Launches Will Drive Future Upside
Analysts have trimmed their price target on Dr. Reddy's Laboratories slightly from ₹1,615 to about ₹1,611, reflecting updated views on future revenue growth, profit margins, and a higher assumed future P/E multiple. What's in the News Launched an over the counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent of Extra strength Pataday Once Daily Relief, targeting temporary relief of itchy eyes from allergens such as pollen, grass and animal dander (USFDA approval).Actualización de narrativa • Jan 06
500124: Biosimilar Approvals Will Support Future Upside As Regulatory Issues Remain Contained
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,615, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions that they view as offsetting each other. What's in the News Dr. Reddy's received five separate orders from the GST Authority for tax demand, interest, and penalties related to alleged excess input tax credit for FY2018-19 to FY2022-23, with penalties of ₹1,89,30,110, ₹80,41,186, ₹3,52,95,063, ₹1,45,04,023 and ₹70,86,675 respectively.Actualización de narrativa • Dec 14
500124: Biosimilar Approvals Will Drive Future Upside Despite Slight Multiple Compression
Analysts have marginally lowered their price target on Dr. Reddy's Laboratories to ₹1,615 from ₹1,626, reflecting a slightly higher discount rate, while also factoring in stronger revenue growth, improved profit margins and a somewhat lower future P E multiple. What's in the News European Commission grants marketing authorization for AVT03, Dr. Reddy's and Alvotech's biosimilar to Prolia and Xgeva, with Dr. Reddy's holding exclusive commercialization rights in the U.S. and semi exclusive rights in Europe and the UK (company announcement) EMA's CHMP earlier issued a positive opinion recommending AVT03 for marketing authorization across the European Economic Area, with a separate submission planned to the UK MHRA under the International Recognition Procedure (company announcement) Dr. Reddy's receives an Establishment Inspection Report from the USFDA, with the inspection classified as Voluntary Action Indicated and officially closed (regulatory filing) Eisai and Dr. Reddy's reach a patent settlement allowing Dr. Reddy's to launch a generic version of cancer drug Lenvima in the U.S. from July 1, 2030, subject to certain contingencies (legal filing) Company launches Tegoprazan in India under the brand name PCAB to treat acid related gastrointestinal diseases, targeting a large and growing acid peptic disease population (product launch) Valuation Changes The fair value estimate has been reduced slightly to ₹1,615 from ₹1,625.93, reflecting a modestly more conservative outlook.Actualización de narrativa • Oct 27
Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities
Analysts have revised their price target for Dr. Reddy's Laboratories upward from ₹1,287.37 to ₹1,300.62. This reflects renewed confidence driven by improved profit margin forecasts, despite marginally lower revenue growth expectations.Actualización de narrativa • Sep 04
Investments In Biosimilars And NRT Will Expand Market Reach, Yet Regulatory Hurdles May Persist
With both revenue growth and net profit margin forecasts steady, analysts maintained their fair value estimate for Dr. Reddy's Laboratories at ₹1287. What's in the News Dr. Reddy's Laboratories and Extrovis AG launched Fluorouracil Cream, 0.5% in the US as an authorized generic, approved by the USFDA.
Nueva narrativa • Nov 13
Regulatory Hurdles And Rising Expenses Threaten To Squeeze Margins And Stifle Growth
Upfront costs from acquisitions and partnerships may pressure short-term earnings and compress net margins.Rentabilidad de los accionistas
| 500124 | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | 4.3% | 1.8% | -0.3% |
| 1Y | 6.3% | 12.6% | -2.8% |
Rentabilidad vs. Industria: Los resultados de 500124 fueron inferiores a los de la industria Indian Pharmaceuticals, que obtuvo un rendimiento del 11.3% el año pasado.
Rentabilidad vs. Mercado: 500124 superó al mercado Indian, que obtuvo un rendimiento del -2.9% el año pasado.
Volatilidad de los precios
| 500124 volatility | |
|---|---|
| 500124 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: 500124 no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Indian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 500124 (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1984 | 27,527 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, junto con sus filiales, opera como empresa farmacéutica integrada en todo el mundo. Opera a través de los segmentos de Genéricos Globales, Servicios Farmacéuticos e Ingredientes Activos (PSAI) y Otros. El segmento de Genéricos Globales de la empresa fabrica y comercializa productos farmacéuticos acabados de prescripción y de venta libre que se comercializan bajo marca o como dosis genéricas acabadas con equivalencia terapéutica a las formulaciones de marca, así como participa en el negocio de productos biológicos.
Resumen de fundamentos de Dr. Reddy's Laboratories Limited
| Estadísticas fundamentales de 500124 | |
|---|---|
| Capitalización bursátil | ₹1.13t |
| Beneficios(TTM) | ₹42.85b |
| Ingresos (TTM) | ₹335.93b |
26.4x
Ratio precio-beneficio (PE)3.4x
Ratio precio-ventas (PS)¿Está 500124 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 500124 | |
|---|---|
| Ingresos | ₹335.93b |
| Coste de los ingresos | ₹158.67b |
| Beneficio bruto | ₹177.26b |
| Otros gastos | ₹134.41b |
| Beneficios | ₹42.85b |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 22, 2026
| Beneficios por acción (BPA) | 51.46 |
| Margen bruto | 52.77% |
| Margen de beneficio neto | 12.76% |
| Ratio deuda/patrimonio | 16.5% |
¿Cómo se ha desempeñado 500124 a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.6%
Rentabilidad actual por dividendo16%
Ratio de pagos¿Paga 500124 dividendos fiables?
Ver historial de dividendos e índices de referencia de 500124| fechas de dividendos de Dr. Reddy's Laboratories | |
|---|---|
| Fecha ex dividendo | Jul 10 2026 |
| Fecha de pago de dividendos | Jul 30 2026 |
| Días hasta ex dividendo | 9 days |
| Días hasta la fecha de pago de dividendos | 29 days |
¿Paga 500124 dividendos fiables?
Ver historial de dividendos e índices de referencia de 500124Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/30 03:04 |
| Precio de las acciones al final del día | 2026/06/30 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Dr. Reddy's Laboratories Limited está cubierta por 69 analistas. 37 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |